Hope in the Fight Against Obesity
For the first time, there’s a glimmer of hope in tackling obesity. Recent data from the National Center for Health Statistics at the CDC indicates that adult obesity rates in the US might finally stabilize after years of annual increases since at least 2011.
Obesity, long understood to be the second leading cause of preventable death in America, is still being met with negative cultural attitudes and ineffective government diet messaging. Yet, like many seemingly insurmountable problems, we’re finding innovative solutions.
Experts suggest that a significant part of these recent advancements can be attributed to powerful new medications known as GLP-1 drugs, like Ozempic and Munjaro. However, alongside their life-changing effects, there’s a concerning rise in an unregulated shadow market.
Multiple websites, med spas, and clinics are offering unauthorized versions of these drugs. These alternatives are often cheaper and easier to access than the originals but come with serious risks—they’re usually untested and poorly regulated.
The FDA has reported that the active ingredients in Ozempic and Munjaro carry serious side effects. Issues have arisen, with some patients ending up in the hospital due to incorrect dosing.
This is somewhat expected, especially since many of these products lack proper labeling or instructions. In 2023 alone, there were nearly 3,000 calls to poison control related to semaglutide, a notable increase from the previous year, with many cases involving improperly labeled variants.
Concerns also linger about the actual contents of these unapproved products. The FDA has warned that some pharmacies are using different, unapproved salt forms of semaglutide, which may not be safe. In April 2025, counterfeit Ozempics were seized after it was found that some vials contained incorrect ingredients or harmful bacteria.
These issues highlight real health risks rather than just technical violations.
During earlier shortages, certain compounded medications were allowed under special circumstances, but those shortages are over, and the FDA has instructed most pharmacies to cease producing these versions. Nevertheless, the illicit trade continues, operating in a gray legal area.
This trend could jeopardize future advancements in obesity treatments.
Companies like Novo Nordisk and Eli Lilly are heavily investing in developing these crucial medications. When the market is flooded with unapproved alternatives, it undermines the potential for innovation. If investors can’t feel confident about returns, the next generation of weight loss drugs might never see the light of day.
Perhaps the biggest concern is public trust. If patients have negative experiences with counterfeit or contaminated drugs, they may lose faith in legitimate weight-loss innovations. This skepticism could make insurance companies and healthcare providers hesitant to back effective treatments for the obesity crisis.
This doesn’t suggest that the formulation should vanish entirely; there will always be patients with specific needs that approved versions can’t meet, such as allergies or unique dosing requirements. But the current situation is not an isolated incident.
The FDA needs to persist in its crackdown on compounding pharmacies that sell unapproved drugs or misleadingly labeled products as “research chemicals.” Simultaneously, insurance companies and legislators should work to make legitimate treatments more affordable by removing intermediaries like pharmacy benefit managers.
No one should have to gamble with their health.
We’re finally seeing progress in addressing a disease that affects nearly half the population and has puzzled policymakers for decades. However, this progress remains fragile.
If unregulated GLP-1 versions dominate the market, we risk reversing the strides reported by the CDC. That could mean shorter lifespans for many, rather than living fully and with dignity.
